#onclive

Risk Stratification for Advanced Melanoma – OncLive

[ad_1]

Transcript:

Jeffrey Weber, MD, PhD: Dirk, if you see a patient either with very locally or regionally advanced or metastatic disease, how do you stratify the patients in your mind, and how do you explain this to the patient? That is, what biomarkers or what criteria do you use to classify the patients in your own mind into risk groups?

Dirk Schadendorf, MD: So, it’s localized disease…

Dr. Hamid on Promising Phase III Trials in Melanoma – OncLive – OncLive

[ad_1]

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses 2 promising, ongoing phase III randomized trials in melanoma.

Some important takeaways from recent phase III trials in this space include both higher response rates and possibly lower toxicity profiles, says Hamid. Plus, biomarker analyses…

Neoadjuvant Therapy for Melanoma – OncLive

[ad_1]

Transcript:

Jeffrey Weber, MD, PhD: Dirk, what about neoadjuvant therapy? We actually, for the first time, heard about a neoadjuvant trial here at ESMO; this was Christian Blank’s study. So, is there a place for neoadjuvant therapy in patients with sort of the bulky high-risk stage IIIc disease, and now we call it stage IIId disease?

Dirk Schadendorf, MD:Yes. I think Caroline already…

Tulane Cancer Center and Its World-Class Teams Join OncLive

PLAINSBORO, N.J. (PRWEB) February 17, 2015

OncLive® and Tulane Cancer Center at the Tulane University School of Medicine have joined forces to promote awareness of new developments in cancer care through OncLive’s Strategic Alliance Partnership program, OncLive announced today.

Through the Strategic Alliance Partnership program, the OncLive editorial and marketing teams will work with Tulane…